POINT Biopharma to Participate in Upcoming Investor Conferences

Rhea-AI Summary

POINT Biopharma Global Inc. (NASDAQ: PNT) announced participation in several upcoming investor conferences. Notable events include the Guggenheim 5th Annual Oncology Conference in New York on February 8, 2023, and the SVB Securities Global Biopharma Conference virtually on February 16, 2023. Other conferences include the Cowen Healthcare Conference in Boston on March 7, 2023, Oppenheimer Healthcare Investor Conference virtually on March 13, 2023, and the Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 25-26, 2023. The company focuses on developing radiopharmaceuticals for cancer treatment and has active clinical trials for its product candidates PNT2004 and PNT2002.

INDIANAPOLIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced management will participate in the following upcoming investor conferences:

Guggenheim 5th Annual Oncology Conference
Format: Fireside Chat and 1x1 Meetings
Location: New York, NY
Date: Wednesday, February 8, 2023
Time: 2:10 pm ET

SVB Securities Global Biopharma Conference
Format: Fireside Chat and 1x1 Meetings
Location: Virtual
Date: Thursday, February 16, 2023
Time: 11:20 am ET

Cowen 43rd Annual Health Care Conference
Format: GI/GU Oncology Panel Discussion and 1x1 Meetings
Location: Boston, MA
Date: Tuesday, March 7, 2023
Time: 12:50pm ET

Oppenheimer 33rd Annual Healthcare Investor Conference
Format: Fireside Chat and 1x1 Meetings
Location: Virtual
Date: Monday, March 13, 2023
Time: 8:40am ET

2023 Bloom Burton & Co. Healthcare Investor Conference
Format: Presentation and 1x1 Meetings
Location: Toronto, ON
Dates: Tuesday, April 25 and Wednesday, April 26, 2023

To access the live webcasts of the presentations (if publicly available) please visit the Investors section of the company’s website at https://www.pointbiopharma.com/investors.

About POINT Biopharma Global Inc.
POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT aims to transform precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 (²²⁵Ac) and lutetium-177 (¹⁷⁷Lu). POINT’s active clinical trials include FRONTIER, the phase 1 trial for PNT2004, a pan-cancer program targeting fibroblast activation protein-α (FAP-α), and SPLASH, the phase 3 trial for PNT2002 for people with metastatic castration resistant prostate cancer (mCRPC) after second-line hormonal treatment. More information about the SPLASH trial can be found at https://www.splashtrial.com/. Learn more about POINT Biopharma Global Inc. at https://www.pointbiopharma.com/.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential attributes and benefits of POINT’s product candidates and the format and timing of POINT’s product development activities and clinical trials. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, our ability to obtain funding for our operations, our ability to maintain the license agreements underlying our product candidates, competition, the ability of POINT to grow and manage growth profitably and retain its key employees, the impact of COVID-19 on POINT’s business, the ability to maintain the listing of POINT’s common stock on the NASDAQ, changes in applicable laws or regulations, the possibility that POINT may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described in POINT's Annual Report on Form 10-K filed with the SEC on March 25, 2022 and subsequent filings with the SEC. Most of these factors are outside of POINT’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact:
Daniel Pearlstein
Associate Director, Corporate Strategy
investors@pointbiopharma.com

FAQ

What investor conferences will PNT participate in February 2023?

PNT will participate in the Guggenheim 5th Annual Oncology Conference on February 8 and the SVB Securities Global Biopharma Conference on February 16, 2023.

When is the Cowen Healthcare Conference for PNT?

The Cowen 43rd Annual Health Care Conference for PNT is scheduled for March 7, 2023.

What is the format of PNT's presentations at the conferences?

PNT's presentations will include fireside chats and 1x1 meetings at various conferences.

Where can I find live webcasts for PNT's investor presentations?

Live webcasts for PNT's presentations can be accessed on the Investors section of their website.

What clinical trials is POINT Biopharma Global Inc. currently conducting?

POINT is conducting clinical trials including the FRONTIER trial for PNT2004 and the SPLASH trial for PNT2002, targeting specific cancer treatments.